Myriad Genetics has added a commercialisation plan to its existing agreement with Pfizer.

Myriad is currently pursuing approval from the US Food and Drug Administration (FDA) for the use of its BRACAnalysis CDx device as a companion diagnostic along with Pfizer’s talazoparib therapy, under the current agreement.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

The new commercialisation plan will enable both the companies to commercialise their respective products, which are under regulatory review.

Based in the US, Myriad is a molecular diagnostic company, while Pfizer, also based in the US, is a pharmaceutical company.

Tencent and Medopad have collaborated for the development of an artificial intelligence (AI) based solution, which will enable remote monitoring of patients with Parkinson’s disease.

Both the companies are also in collaboration with Parkinson’s Center of Excellence at King’s College Hospital, London, UK, to receive support for the project.

Medopad is developing a new app, which is designed to provide video tests to analyse the hand movements for remote examination of patients by doctors. Tencent will work with Medopad to include a new AI-software in the app to automatically score the tests.

“The new services will be based on Philips’ Cloud-based HealthSuite digital platform and will address various self-medication issues of patients suffering from chronic diseases.”

Based in China, Tencent is a technology company, while Medopad is a healthcare technology company based in the UK.

Stryker has collaborated with Synaptive Medical and Ziehm Imaging to strengthen its position in the surgical guidance field.

The collaboration includes the provision of Stryker’s BrightMatter Plan software to Synaptive Medical to enable the delivery of whole-brain tractography. Stryker will also provide Ziehm Imaging’s Ziehm Vision RFD 3D C-arm to produce high-quality images.

The transaction will enable Stryker to provide a comprehensive solution to patients for surgical guidance.

Based in the US, Stryker is a medical technology company, while Synaptive Medical is a Canada-based medical device and technology firm and Ziehm Imaging is a Germany-based developer and manufacturer of mobile C-arms.

Royal Philips and Ypsomed have entered a memorandum of understanding for the co-development and deployment of digital services.

The new services will be based on Philips’ Cloud-based HealthSuite digital platform and will address various self-medication issues of patients suffering from chronic diseases such as diabetes.

Based in the Netherlands, Royal Philips is a health technology company, while Ypsomed is a Switzerland-based developer of injection and infusion systems for self-medication.